Healthcare has always been a sensitive domain simultaneously being the most adaptive to disruptive technologies and thereby, registering several discoveries within. Otherwise, who has ever thought that breakthroughs such as prosthetics will even serve the need for natural body parts as their replacement. Going back to the technological adaptation, healthcare has successfully deployed Artificial Intelligence (AI) as a result of which precision medicine seems to be benefitted the most out of it. In this respect, a startup that is developing AI-powered precision medicine technology has recently made a remarkable announcement. The startup, GNS Healthcare has announced on 7th January 2020 about the extension of its Series D funding round which was followed by an investment from the Merck Global Health Innovation Fund.
The Series D of the funding round was at first announced in July, with a few investors name including Celgene, Amgen Ventures, Cigna Ventures, and several others that overall contributed a sum of $23 million. The recent infusion, in this addition, brought the total raised amount to nearly $28 million in the round. As far as the allocation of funds is concerned, GNS Healthcare will deploy this raised funding so as to advance the development of its software. GNS uses AI to anticipate the responses of patients while taking various treatments. It further records and shares the resulting data with various health plan partners, and pharmaceutical and biotechnology partners as well. This process helps in drug discovery and eases the matching of the patients to the most effective treatments.
